Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOC™) to deliver RNA therapeutics that target the underlying genetic causes of rare muscle diseases such as myotonic dystrophy and Duchenne muscular dystrophy. Their platform enables precise treatment delivery to previously inaccessible tissues, addressing significant unmet medical needs in the field of genetic disorders.
Funding
$345.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many rare muscle diseases, such as myotonic dystrophy and Duchenne muscular dystrophy, lack effective treatments because it is difficult to deliver therapeutics precisely to the affected muscle tissues. Traditional drug delivery methods often fail to reach the specific cells responsible for the disease, limiting their efficacy. This challenge hinders the development of targeted therapies that address the underlying genetic causes of these disorders.
Solution
Avidity Biosciences is developing Antibody Oligonucleotide Conjugates (AOCs), a new class of RNA therapeutics designed to overcome the limitations of traditional drug delivery. The AOC platform combines the specificity of monoclonal antibodies with the precision of oligonucleotides to deliver RNA therapeutics directly to previously inaccessible muscle tissues and cells. This targeted approach enables the development of treatments that address the underlying genetic drivers of rare muscle diseases. By precisely targeting the affected tissues, Avidity aims to improve treatment efficacy and address the unmet medical needs of patients with these debilitating conditions.
Target Audience
The primary target audience includes patients suffering from rare muscle diseases, such as myotonic dystrophy and Duchenne muscular dystrophy, and their families, as well as medical professionals specializing in the treatment of these conditions.
Features
- AOC platform combines monoclonal antibodies and oligonucleotides for targeted drug delivery.
- Designed to deliver RNA therapeutics directly to muscle tissues and cells.
- Targets the underlying genetic causes of rare muscle diseases.
- Aims to improve treatment efficacy compared to traditional methods.
- Pipeline programs focused on myotonic dystrophy, Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.